<DOC>
	<DOCNO>NCT01677247</DOCNO>
	<brief_summary>This randomize , single blind , two-period , two sequence cross-over study fast condition compare bioavailability two glimepiride 4 mg tablet formulation ( test reference formulation ) .</brief_summary>
	<brief_title>Bioequivalence Study 4 mg Glimepiride Tablet</brief_title>
	<detailed_description>The participate subject require overnight fast ; next morning give orally either one tablet 4 mg glimepiride test drug ( produce PT Dexa Medica ) one tablet 4 mg glimepiride ( AmarylÂ® , Sanofi Aventis ) reference drug 200 mL water . Blood sample draw immediately take drug ( control ) , 0.5 , 1 , 1.5 , 2 , 2.5 , 3 , 3.5 , 4.5 , 6 , 9 , 12 , 18 24 hour drug administration . Immediately drug administration , subject administer 100 ml 10 % glucose approximately 0.5 , 1.5 , 2 , 2.5 , 3.5 , 4.5 hour . In addition , 20 % glucose solution give subject exhibit symptom hypoglycaemia . One week first drug administration ( wash-out period ) , procedure repeat use alternate drug . The plasma concentration glimepiride determine high performance liquid chromatography ultraviolet detection ( HPLC-UV ) . The pharmacokinetic parameter assess AUCt , AUCinf , Cmax , tmax , t1/2 .</detailed_description>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>1 . Male female subject absence significant disease clinically significant abnormal laboratory value laboratory evaluation , medical history physical examination screen 2 . Age 18 55 year 3 . Preferably nonsmoker moderate smoker ( less 10 cigarette per day ) 4 . Able participate , communicate well investigator willing provide write informed consent participate study 5 . BMI 18 25 kg/m2 6 . Vital sign ( 10 minute rest ) must within follow range : SBP 100 120 mmHg DBP 60 80 mmHg Pulse rate 60 90 bpm 1 . Personal/family history allergy hypersensitivity contraindication glimepiride ally drug 2 . Pregnant lactate woman 3 . Any major illness past 90 day clinically significant ongoing chronic medical illness 4 . Presence clinically significant abnormal value screen 5 . Positive Hepatitis B surface antigen ( HBsAg ) , antiHCV , antiHIV 6 . Clinically significant haematology abnormality 7 . Clinically significant electrocardiogram ( ECG ) abnormalities 8 . Any surgical medical condition ( present history ) might significantly alter absorption , distribution , metabolism excretion study drug 9 . Past history anaphylaxis angioedema 10 . History drug alcohol abuse within 12 month prior screen 11 . Participation clinical trial within past 90 day 12 . History bleed coagulative disorder 13 . History difficulty donate blood difficulty accessibility vein leave right arm 14 . A donation loss 500 mL ( ) blood within 3 month study 's first dose day 15 . Intake prescription , nonprescription drug , food supplement herbal medicine within 14 day study 's first dosing day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>sulphonylurea</keyword>
	<keyword>anti-hyperglycaemic</keyword>
	<keyword>bioavailability</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>glimepiride</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>